Morgan Stanley
SGP

Morgan Stanley’s SpyGlass Pharma SGP Stock Holding History

Morgan Stanley’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$199K Buy
8,921
+4,742
+113% +$103K ﹤0.01% 5957
2026
Q1 		$108K Buy
+4,179
New +$112K ﹤0.01% 6119

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Morgan Stanley's SGP Position: Q2 2026 in Review

Morgan Stanley increased its SpyGlass Pharma (SGP) stake by 113% in Q2 2026, buying an estimated $103K and bringing the position to 8,921 shares worth $199K. The position accounts for ﹤0.01% of the portfolio, ranked #5957.

Morgan Stanley first reported a position in SGP in Q1 2026 and has held it in 2 quarters since. 43 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • Morgan Stanley held 8,921 shares of SpyGlass Pharma worth $199K as of Q2 2026.
  • Morgan Stanley bought 4,742 SpyGlass Pharma shares in Q2 2026, an estimated $103K.
  • SpyGlass Pharma made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5957 holding.
  • Morgan Stanley first reported a position in SpyGlass Pharma in Q1 2026 and has held it in 2 quarters since.
  • 43 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.